PSA倍增时间评估前列腺癌进展的临床应用现状
摘要
监测血清PSA浓度是前列腺癌诊断和预后评估的常用工具，PSA倍增时间（PSADT）是通过血清PSA动力学研究得到的监测指标，可评估前列腺癌疾病进展。本文介绍PSADT的计算方法，检索文献并阐述PSADT在预测前列腺癌根治术后临床复发、放疗后临床进展、前列腺癌带瘤生存时间和特异死亡率、挽救性局部治疗疗效及监测观察等待治疗患者的回顾性研究情况，评价PSADT的应用价值。
出处
《国际泌尿系统杂志》
2008年第3期304-308,共5页
International Journal of Urology and Nephrology
参考文献27
-
1Brawer MK, Chetner MP, Beatie J, et al Screening for prostatic carcinoma with prostate specific antigen J Urol, 1992, 174 : 841 - 845.
-
2Carter HB, Pearson JD PSA velocity for the diagnosis of early prostate cancer. A new concept Urol Clin North Am, 1993, 20:665 -670.
-
3Roberts SG, Blute ML, Bergstralh EJ, et al PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer Mayo Clin Proc, 2001,76:576 -581.
-
4Pollack A, Zagars GK, Kavadi VS Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer Cancer, 1994, 74:670-678.
-
5Freedland S J, Humphreys EB, Mangold LA, et al Risk of prostate cancer - specific mortality following biochemical recurrence after radical prostatectomy. JAMA,2005, 294:433 - 439.
-
6D'Amico AV, Cote K, Loffredo M, et al Determinants of prostate cancer specific survival following radiation herapy during the prostate specific antigen era J Urol, 2003, 170:S42 -46.
-
7Tomioka S, Shimbo M, Amiya Y, et al Significance of prostate - specific antigen - doubling time on survival of patients with hormone refractory prostate cancer and bone metastasis: Analysis on 56 cases of cancer - specific death int J Urol, 2007, 14:123 - 127.
-
8Ward JF, Zincke H, Bergstralh EJ, et al Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy J Urol, 2004, 172 : 2244 - 2248.
-
9Spiess PE, Lee AK, Leibovici D, et al Presalvage prostate -specific antigen (PSA) and PSA doubling time as predictors of biochemical failure of salvage cryotherapy in patients with locally recurrent prostate cancer after radiotherapy Cancer, 2006, 107 : 275 - 280.
-
10Ali K, Gunnar A, Jan - Erik D, et al PSA doubling time predicts the outcome after active surveillance in screening - detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section Int J Cancer, 2007, 120:170 - 174.
-
1俞世成,李新德.前列腺癌根治性治疗后生化复发的诊治进展[J].肿瘤学杂志,2010,16(7):578-581.
-
2任如龙,马俐.日本对肿瘤标记物NSE的临床应用现状[J].日本医学介绍,1991,12(10):476-477.
-
3杨玉波,张强,潘克勤.门静脉5—Fu化疗预防大肠癌肝转移的临床应用现状[J].实用肿瘤学杂志,2000,14(2):157-159. 被引量：3
-
4赵燕,张茹.厄洛替尼治疗非小细胞肺癌的机制、现状与展望[J].中国药物警戒,2010,7(10):617-619. 被引量：3
-
5立彦,夏伟,瞿卫,王自正.生长抑素及其受体的研究与临床应用现状[J].国外医学（临床生物化学与检验学分册）,2004,25(6):529-531. 被引量：6
-
6胡成,高新,Loeb S.术前PSA倍增时间的长短对前列腺癌根治术后生化复发无明显影响[J].中华腔镜泌尿外科杂志（电子版）,2010,4(4):58-58.
-
7张先有.前列腺癌的预防与治疗——前列腺癌防治系列（三）[J].家庭用药,2002(12):15-15.
-
8赵国栋,刘士军,胡浩.前列腺偶发癌的临床分期及治疗方案与预后的相关性研究[J].临床和实验医学杂志,2014,13(12):1014-1016. 被引量：5
-
9许红,宋爱华.前列腺特异性抗原的初步应用[J].癌症,1996,15(5):355-357. 被引量：1
-
10卢丽萍.血清PSA值和直肠指检在前列腺癌诊断中的价值[J].中国现代医药杂志,2006,8(6):25-26.
